Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamer E Fandy

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Current Medicinal Chemistry|June 13, 2009
Development of DNA methyltransferase inhibitors for the treatment of neoplastic diseasesTamer E Fandy
The Senior Care Pharmacist|March 23, 2023
<i>Responding to</i> "Antipsychotics and Parkinson's Disease: A Troubling Mix"Tamer E Fandy
Epigenomes|July 25, 2023
Therapeutic Applications of Azanucleoside Analogs as DNA Demethylating AgentsFallon Gallimore, Tamer E Fandy
Epigenomics|November 30, 2011
Epigenetic targets in human neoplasmsTamer E Fandy, Steven D Gore
Cancer Chemotherapy and Pharmacology|January 26, 2006
Trichostatin A sensitizes TRAIL-resistant myeloma cells by downregulation of the antiapoptotic Bcl-2 proteinsTamer E Fandy, Rakesh K Srivastava
Advances in Cancer Research|August 6, 2021
DNA methylation inhibitors: Retrospective and perspective viewMd Gias Uddin, Tamer E Fandy
The Senior Care Pharmacist|July 26, 2022
Management of Parkinson's Disease PsychosisHanan Elsibai, Mena Kualleny, Tamer E Fandy
International Journal of Molecular Sciences|November 13, 2025
Current Status of Molecularly Targeted Therapeutics in Blood CancersCaitlin Kumala, Lynh Vu, Tamer E Fandy
Cancer Journal (Sudbury, Mass.)|April 28, 2007
DNA demethylating agents and histone deacetylase inhibitors in hematologic malignanciesTamer E Fandy, Hetty Carraway, Steven D Gore
Molecular Cancer|July 2, 2008
Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cellsTamer E Fandy, Sharmila Shankar, Rakesh K Srivastava
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Current Medicinal Chemistry|June 13, 2009
Development of DNA methyltransferase inhibitors for the treatment of neoplastic diseasesTamer E Fandy
The Senior Care Pharmacist|March 23, 2023
<i>Responding to</i> "Antipsychotics and Parkinson's Disease: A Troubling Mix"Tamer E Fandy
Epigenomes|July 25, 2023
Therapeutic Applications of Azanucleoside Analogs as DNA Demethylating AgentsFallon Gallimore, Tamer E Fandy
Epigenomics|November 30, 2011
Epigenetic targets in human neoplasmsTamer E Fandy, Steven D Gore
Cancer Chemotherapy and Pharmacology|January 26, 2006
Trichostatin A sensitizes TRAIL-resistant myeloma cells by downregulation of the antiapoptotic Bcl-2 proteinsTamer E Fandy, Rakesh K Srivastava
Advances in Cancer Research|August 6, 2021
DNA methylation inhibitors: Retrospective and perspective viewMd Gias Uddin, Tamer E Fandy
The Senior Care Pharmacist|July 26, 2022
Management of Parkinson's Disease PsychosisHanan Elsibai, Mena Kualleny, Tamer E Fandy
International Journal of Molecular Sciences|November 13, 2025
Current Status of Molecularly Targeted Therapeutics in Blood CancersCaitlin Kumala, Lynh Vu, Tamer E Fandy
Cancer Journal (Sudbury, Mass.)|April 28, 2007
DNA demethylating agents and histone deacetylase inhibitors in hematologic malignanciesTamer E Fandy, Hetty Carraway, Steven D Gore
Molecular Cancer|July 2, 2008
Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cellsTamer E Fandy, Sharmila Shankar, Rakesh K Srivastava
Pageof 4